Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Provectus Biopharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$2.43M. For fiscal 2025 it was -$3.33M. The highest annual figure on record is -$1.01M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.33M | – |
| FY2024 | Dec 31, 2024 | -$3.28M | – |
| FY2023 | Dec 31, 2023 | -$2.57M | – |
| FY2022 | Dec 31, 2022 | -$3.04M | – |
| FY2021 | Dec 31, 2021 | -$1.01M | – |
| FY2020 | Dec 31, 2020 | -$4.09M | – |
| FY2019 | Dec 31, 2019 | -$6.19M | – |
| FY2018 | Dec 31, 2018 | -$5.20M | – |
| FY2017 | Dec 31, 2017 | -$10.35M | – |
| FY2016 | Dec 31, 2016 | -$21.94M | – |
| FY2015 | Dec 31, 2015 | -$17.41M | – |
| FY2014 | Dec 31, 2014 | -$13.85M | – |
| FY2013 | Dec 31, 2013 | -$9.89M | – |
| FY2012 | Dec 31, 2012 | -$11.26M | – |
| FY2011 | Dec 31, 2011 | -$17.20M | – |
| FY2010 | Dec 31, 2010 | -$13.73M | – |
| FY2009 | Dec 31, 2009 | -$8.60M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$358.25K | – |
| Q1 FY2026 | Mar 31, 2026 | -$357.57K | – |
| Q4 FY2025 | Dec 31, 2025 | -$869.55K | – |
| Q3 FY2025 | Sep 30, 2025 | -$839.87K | – |
| Q2 FY2025 | Jun 30, 2025 | -$523.13K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$912.01K | – |
| Q3 FY2024 | Sep 30, 2024 | -$565.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$762.59K | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$561.21K | – |
| Q3 FY2023 | Sep 30, 2023 | -$768.87K | – |
| Q2 FY2023 | Jun 30, 2023 | -$617.78K | – |
| Q1 FY2023 | Mar 31, 2023 | -$624.11K | – |
| Q4 FY2022 | Dec 31, 2022 | -$754.79K | -146.5% |
| Q3 FY2022 | Sep 30, 2022 | -$816.58K | – |
| Q2 FY2022 | Jun 30, 2022 | -$877.89K | – |
| Q1 FY2022 | Mar 31, 2022 | -$592.22K | – |
| Q4 FY2021 | Dec 31, 2021 | $1.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$815.66K | – |
| Q2 FY2021 | Jun 30, 2021 | -$706.14K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$957.56K | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.44M | – |
| Q2 FY2020 | Jun 30, 2020 | -$967.77K | – |
| Q1 FY2020 | Mar 31, 2020 | -$716.32K | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.14M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.49M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.49M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.07M | – |
| Q4 FY2018 | Dec 31, 2018 | -$810.28K | – |
| Q3 FY2018 | Sep 30, 2018 | -$919.50K | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.74M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.74M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.47M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.29M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.36M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.23M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.01M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.00M | – |
See a number that looks wrong?